Dr. Kleanthis Xanthopoulos grew up in Drapetsona, a refugee neighborhood outside Athens built by Pontic Greeks who fled ...

Dr. Kleanthis Xanthopoulos grew up in Drapetsona, a refugee neighborhood outside Athens built by Pontic Greeks who fled the 1922 catastrophe. He went on to co-found multiple biotech companies in the United States, help develop drugs against Hepatitis C and kidney disease, and build a medical device used in over 5,000 brain hemorrhage patients who survived because of it. His first company, Aurora Biosciences, was acquired by Vertex Pharmaceuticals. His second, Anadys Pharmaceuticals, produced a Hepatitis C drug that Roche acquired. A third company, Regulus Therapeutics, developed a kidney disease treatment that Novartis bought. He also helped engineer IRRAFLOW, a device that has kept more than 5,000 hemorrhagic stroke patients alive. Xanthopoulos was awarded the ARGO Prize for Innovation in 2025, an annual award recognizing Greeks who excel abroad. He told ERT News that the feeling of discovering a drug is unlike anything else, but was quick to add that no drug gets made alone. Development typically takes 12 to 15 years, costs enormous sums, and fails far more often than it succeeds. He participated in the Human Genome Project early in his career, which he described as one of three turning points that shaped his path. The third and most decisive, he said, was realizing that scientific discovery alone is worthless without the funding structures and commercial infrastructure to deliver it to patients. He now leads the Athens LifeTech Park initiative, which aims to grow biotech startups in Greece and Europe. He has spoken publicly about what Greece is missing to stop losing its brightest minds overseas, including what changes would make Athens a real innovation hub in life sciences. On the ethical weight of leadership, he said the hardest part of running companies worth billions is not the money. It is knowing that scientists, investors, and patients all depend on the decisions you make. #Greece #Biotech #GreekDiaspora